JP2019535232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535232A5 JP2019535232A5 JP2019502698A JP2019502698A JP2019535232A5 JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5 JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding portion
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022035222A JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614162.4A GB201614162D0 (en) | 2016-08-18 | 2016-08-18 | Antibodies, uses thereof and conjugates thereof |
| GB1614162.4 | 2016-08-18 | ||
| PCT/GB2017/052448 WO2018033749A1 (en) | 2016-08-18 | 2017-08-18 | Anti-psma antibodies, uses thereof and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035222A Division JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535232A JP2019535232A (ja) | 2019-12-12 |
| JP2019535232A5 true JP2019535232A5 (enExample) | 2020-09-17 |
| JP7039554B2 JP7039554B2 (ja) | 2022-03-22 |
Family
ID=57045541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502698A Active JP7039554B2 (ja) | 2016-08-18 | 2017-08-18 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
| JP2022035222A Active JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035222A Active JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11059903B2 (enExample) |
| EP (2) | EP4403226A3 (enExample) |
| JP (2) | JP7039554B2 (enExample) |
| CN (1) | CN110049999B (enExample) |
| ES (1) | ES2983492T3 (enExample) |
| GB (1) | GB201614162D0 (enExample) |
| WO (1) | WO2018033749A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| KR20200130709A (ko) * | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| SG11202009670RA (en) * | 2018-03-29 | 2020-10-29 | Ambrx Inc | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
| EP3994177A4 (en) * | 2019-07-02 | 2023-09-20 | Telix International Pty Ltd | PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR |
| CN114729059A (zh) | 2019-09-11 | 2022-07-08 | 宾夕法尼亚大学董事会 | 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法 |
| CN113677704B (zh) * | 2019-11-22 | 2024-03-26 | 南通壹宸生物医药科技有限公司 | Psma抗体及其应用 |
| CN110922486B (zh) * | 2020-02-18 | 2020-05-22 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| IL322523A (en) * | 2023-02-28 | 2025-10-01 | Eisai R&D Man Co Ltd | Anti-PSMA antibodies, conjugates and methods of use |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| WO2026044149A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthesis of drug-linker combinations for antibody-drug conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| CN1294588C (zh) | 1996-07-24 | 2007-01-10 | 皇家菲利浦电子有限公司 | 光盘录取装置 |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ES2386366T3 (es) | 2005-02-18 | 2012-08-17 | Medarex, Inc. | Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA) |
| CA2598454C (en) * | 2005-02-18 | 2013-04-09 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US9364557B2 (en) | 2007-08-01 | 2016-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fold-back diabody diphtheria toxin immunotoxin and methods of use |
| US20100239517A1 (en) | 2007-10-09 | 2010-09-23 | Stephen Brocchini | Novel conjugated proteins and peptides |
| CN101891818B (zh) * | 2009-01-16 | 2012-07-25 | 中国人民解放军第四军医大学 | 抗人前列腺特异性膜抗原胞外区单链抗体及其应用 |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| BR112014031613A2 (pt) * | 2012-06-19 | 2017-07-25 | Polytherics Ltd | processo para preparação de conjugados de anticorpos e conjugados de anticorpos |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| ES2623209T3 (es) | 2012-10-24 | 2017-07-10 | Polytherics Limited | Conjugados fármaco-proteína |
| AU2014386824B2 (en) * | 2013-03-15 | 2019-05-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2015057250A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| JP6908964B2 (ja) | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| DK3151865T3 (da) * | 2014-05-22 | 2021-10-25 | Byondis Bv | Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| EP3220956B1 (en) * | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
| KR20200130709A (ko) * | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
-
2016
- 2016-08-18 GB GBGB1614162.4A patent/GB201614162D0/en not_active Ceased
-
2017
- 2017-08-18 WO PCT/GB2017/052448 patent/WO2018033749A1/en not_active Ceased
- 2017-08-18 CN CN201780044227.8A patent/CN110049999B/zh active Active
- 2017-08-18 EP EP24173428.4A patent/EP4403226A3/en active Pending
- 2017-08-18 US US16/303,600 patent/US11059903B2/en active Active
- 2017-08-18 ES ES17757849T patent/ES2983492T3/es active Active
- 2017-08-18 JP JP2019502698A patent/JP7039554B2/ja active Active
- 2017-08-18 EP EP17757849.9A patent/EP3500595B1/en active Active
-
2022
- 2022-03-08 JP JP2022035222A patent/JP7486538B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527561A5 (enExample) | ||
| Tran et al. | 99mTc-maEEE-ZHER2: 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors | |
| Wängler et al. | Antibody− dendrimer conjugates: The number, not the size of the dendrimers, determines the immunoreactivity | |
| Hong et al. | Positron emission tomography imaging of prostate cancer | |
| Adumeau et al. | A pretargeted approach for the multimodal PET/NIRF imaging of colorectal cancer | |
| Westerlund et al. | Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic affibody molecules | |
| TWI795415B (zh) | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 | |
| ES2800602T3 (es) | Procedimientos y composiciones relacionados con los fragmentos de anticuerpos monocatenarios que se unen a la glucoproteína 72 asociada a tumor (TAG-72) | |
| JP2017531028A5 (enExample) | ||
| JP2020504607A5 (enExample) | ||
| JP2019511201A5 (enExample) | ||
| CA2646329A1 (en) | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting | |
| TWI780082B (zh) | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 | |
| Maina et al. | From bench to bed: New gastrin-releasing peptide receptor-directed radioligands and their use in prostate cancer | |
| ES2925224T3 (es) | Anticuerpos monoclonales humanos contra EphA4 y su uso | |
| EP4403226A3 (en) | Anti-psma antibodies, uses thereof and conjugates thereof | |
| Luo et al. | Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer | |
| Spiegelberg et al. | CD44v6‐Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody‐Based Approaches | |
| CA3168866A1 (en) | Anti-meflin antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody | |
| Uehara et al. | 67/68Ga-labeling agent that liberates 67/68Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels | |
| Kim et al. | Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging | |
| Altai et al. | Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine | |
| Niu et al. | Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression | |
| Altıparmak Güleç et al. | Radiopharmaceuticals developed for 89Zr-Immuno-PET | |
| WO2024097950A1 (en) | Radionucleotide and near-infrared dye conjugated antibody for detection of gd2-positive cancer |